Skip to main content

2021

Rutgers launches studies of new HIV prevention medication in Newark

Nov 30, 2021

By Kithmy Wickramasinghe

Rutgers New Jersey Medical School (NJMS) Research with a Heart is looking for people to participate in two studies assessing the effectiveness of an HIV prevention medication.

Rutgers researchers study medication to curb spread of HIV

Nov 16, 2021

By Leah Mishkin

The COVID-19 pandemic has overshadowed major health issues that still impact New Jersey, putting things like HIV prevention on the back burner for public attention. But urban parts of the state like Essex and Hudson counties continue to see relatively high rates of HIV transmission. Dr. Shobha Swaminathan, Rutgers New Jersey Medical School associate professor, is the principal investigator for two new studies in Newark of a new medicine that may help curb the spread of HIV.

Rutgers Launches IMPOWER HIV Prevention Studies in Newark

Nov 9, 2021

By Rutgers University-New Brunswick

Rutgers New Jersey Medical School Research with a Heart is recruiting participants for the MERCK– IMPOWER studies to assess an HIV prevention oral medication on sexual minority groups.

Rutgers Launches IMPOWER HIV Prevention Studies in Newark

Nov 9, 2021

By Modesta (Maud) Alobawone

Rutgers New Jersey Medical School Research with a Heart is recruiting participants for the MERCK– IMPOWER studies to assess an HIV prevention oral medication on sexual minority groups.

Here’s how experts say you should talk to someone who is hesitant or says no to the vaccine

Jul 30, 2021

By Karin Price Mueller

The overwhelming majority of people who have been hospitalized and have died of the coronavirus are unvaccinated, according to data from state and federal health officials.

Rutgers Begins COVID-19 Prevalence Study in Newark

April 16, 2021

By Tehsuan Glover

Rutgers will help determine the prevalence of the coronavirus in Newark, one of the cities hardest hit by the pandemic, as part of the National Institutes of Health COVID-19 Prevention Network (CoVPN) response to the deadly global outbreak.

Rutgers Begins COVID-19 Prevalence Study in Newark

April 5, 2021

By Rutgers University-New Brunswick

Newswise — Rutgers will help determine the prevalence of the coronavirus in Newark, one of the cities hardest hit by the pandemic, as part of the National Institutes of Health COVID-19 Prevention Network (CoVPN) response to the deadly global outbreak.

Moderna COVID-19 Vaccine Side Effects: How Long They Last

April 5, 2021

By Modesta (Maud) Alobawone

Researchers recruit participants to foster relationships in the community and better understand pandemic’s impact.

Moderna COVID-19 Vaccine Side Effects: How Long They Last

March 11, 2021

By Julia Ries;
Fact checked by Dana K. Cassell

Over 47 million doses of the Moderna vaccine have been administered to U.S. adults since the FDA issued emergency use authorization for the shot on December 18, 2020.

The principal investigators of the Moderna and Johnson & Johnson COVID-19 vaccine clinical trials at Rutgers discuss how the university became a site, and their challenges and successes

March 3, 2021

By Patti Verbanas

In the race to develop a vaccine to battle the coronavirus, Rutgers has served as a site for Phase 3 COVID-19 clinical trials for two of the country’s pharmaceutical giants.

COVID-19 and victim-blaming has made it more difficult to care for people living with HIV/AIDS | Opinion

Updated Feb 15, 2021;
Posted Feb 14, 2021

By Perry N. Halkitis, Shobha Swaminathan and Travis Love

Two notable researchers at Rutgers University and a community educator continue to call on legislators to enact the policies developed by the Statewide Task Force to End the HIV Epidemic. To explain more about HIV/AIDS efforts in New Jersey, Rutgers School of Public Health and Rutgers Medical School will hold “Neutral Nation,” a series of events from Feb. 17 to 20.